Posted by Michael Wonder on 06 May 2026
Healyth Canada authorised Lilly's Kisunla (donanemab), a new treatment for early Alzheimer's disease
4 May 2026 - Today, after more than 35 years of commitment to advancing Alzheimer's research, Lilly Canada announced Health Canada's approval of Kisunla (donanemab).
Kisunla is approved as a once monthly treatment for people living with early symptomatic Alzheimer's disease.
